Physician profile
Robert Rothstein
NPI 1447368543
$5,861.60
in general payments reported to CMS, 2019-2025
30 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $180 · 2021: $764 · 2022: $1,208 · 2023: $998 · 2024: $942 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.21 |
| Education | $135.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $559.26 | 2019-2025 | Cequa, Xelpros |
| Amgen INC. | $525.44 | 2024-2025 | Tepezza, Uplizna |
| Alcon Vision LLC | $473.93 | 2021-2025 | Simbrinza, Hydrus Microstent |
| Oyster Point Pharma, INC. | $466.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $421.91 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Horizon Therapeutics Plc | $396.55 | 2019-2023 | Tepezza, Uplizna |
| Novartis Pharmaceuticals Corporation | $294.50 | 2021-2023 | |
| Allergan, INC. | $290.19 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $272.62 | 2019-2021 | |
| Visionix USA, INC | $258.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $240.49 | 2022-2025 | Acthar |
| Thea Pharma INC. | $213.32 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.05 | 2019-2021 | |
| Abbvie INC. | $158.53 | 2022-2023 | Durysta, Vuity, Lumigan |
| Harrow Eye, LLC | $148.19 | 2024-2025 | Vevye |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $143.66 | 2024-2025 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $115.31 | 2019-2025 | Ultomiris, Soliris |
| Johnson & Johnson Surgical Vision, INC. | $100.34 | 2021 | |
| Sight Sciences, INC. | $99.13 | 2022-2023 | Omni Surgical System |
| Argenx US, INC. | $93.39 | 2024-2025 | Vyvgart Hytrulo |
| Eyevance Pharmaceuticals LLC | $90.72 | 2019-2022 | |
| Dompe US, INC. | $83.88 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $48.93 | 2019 | |
| Akorn Operating Company LLC | $44.86 | 2021 | |
| Shire North American Group INC | $38.46 | 2019 | |
| Glaukos Corporation | $29.80 | 2024 | Idose |
| Ucb, INC. | $24.60 | 2023 | |
| Akorn, INC. | $20.44 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| New World Medical,INC. | $18.48 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.